Find any Australian or New Zealand company or fund (dead or alive) by using SEARCH above or go directly to the site:
|
|
07 November 2024
| Name: | JAYEX TECHNOLOGY LIMITED (JTL) | ||||||
| ISIN: | AU0000155293 | ||||||
| Date of Listing: | 17 December 2015 | ||||||
| Date of Delisting: | 06 August 2024 | ||||||
| Former Names: |
|
Stock Exchange Status:
This entity was delisted from the Australian Securities Exchange on 06 August 2024.Legal Status:
ACN: 119 122 477ABN: 15 119 122 477
Registration Date: 04 April 2006
Capital Gains Tax (CGT) Status:
The securities in this entity, in our opinion, are of little or no value. We have made that assessment by reference to the circumstances leading to a suspension and/or delisting, the length of a suspension, share trading history and last on-market share price, most recent financial and cash flow statements, prospects (including likelihood of re-financing), and other factors including in particular whether the entity is in external administration. If you are seeking to crystallise a capital loss on your securities, that process can be easily and quickly initiated at our online Worthless Shares facility here: https://www.delisted.com.au/sell-worthless-and-other-securities/.
Updates, corrections, disagreements please email to admin@delisted.com.au
Further information: deListed and InvestoGain are operated by Investogain Pty Limited which is licensed by ASIC as an Australian Financial Services Licensee (AFSL 334036). deListed acquires only securities that it deems to be of little or no value, in circumstances where the holder is unable to sell their securities on-market in the normal manner. This service has been provided online via the company’s website www.delisted.com.au since 2004.
Getting advice: Information provided in this section is of a general nature and applicable only to Australian tax residents who hold their investments on capital account (ie for long-term investment purposes). It has been prepared without taking into account your financial needs or tax situation. Before acting on the information, deListed suggests that you consider whether it is appropriate for your circumstances and recommends that you seek independent legal, financial, or taxation advice.
Disclaimer: The information provided above is to the best of our knowledge accurate as of today. But you should bear in mind that it is of a general nature and does not constitute financial or tax advice. Investogain Pty Limited accepts no liability for any loss arising from reliance on this information, including reliance on information that is no longer current.
| Company | FROM | TO |
|---|---|---|
| JAYEX TECHNOLOGY LIMITED | 01/06/2021 | |
| JAYEX HEALTHCARE LIMITED | 01/06/2021 |
REGISTRY:
Automic Registry Pty Ltd
Level 5, 191 ST GEORGES TERRACE PERTH WA 6000
Tel : +61 (2) 8072 1400 or 1300 288 664 (within Australia)
RegistryWebsite RegistryEmail
Shareholders in this company should consider crystallising a capital loss in 2024/25 by selling their shares. This process is now much easier and quicker. It can be achieved online by entering transaction details here. While, this usually makes good economic sense we recommend you seek professional advice before buying or selling securities, your accountant is probably the best person. | 13/09/2024 |
delisted at entity's request under Listing Rule 17.11 | 06/08/2024 |
we understand the company delisted from ASX because of the lack of liquidity on ASX, difficulties associated with fundraising as a listed company, a disproportionate impact on share price of the small number of trades on ASX, costs of the listing and the fact the company's business is now entirely based in the UK | 06/08/2024 |
The company lodged its June 2024 Quarterly Activity Report and June 2024 Appendix 4C. | 05/08/2024 |
The securities of the Company will be suspended from quotation under Listing Rule 17.5 from the commencement of trading today, Thursday, 1 August 2024, for not lodging the relevant periodic report by the due date. If the report is lodged between the closure of the market announcements office on Wednesday, 31 July 2024, and the imposition of the suspension, the entity's securities will normally be reinstated to quotation on the next trading day after the suspension is imposed. | 01/08/2024 |
The suspension of trading in the securities of Jayex Technology Limited will be lifted from the commencement of trading on Monday, 6 May 2024 following lodgement of its Annual Report for the period ending 31 December 2023. | 03/05/2024 |
The company releases its Appendix 4G and Corporate Governance Statement. | 03/05/2024 |
The company releases its annual report. | 03/05/2024 |
The securities of the company will be suspended from quotation under Listing Rule 17.5 from the commencement of trading today, Tuesday, 2 April 2024, for not lodging the relevant periodic report by the due date. If the report is lodged between the closure of the market announcements office on Thursday, 28 March 2024, and the imposition of the suspension, the entity's securities will normally be reinstated to quotation on the next trading day after the suspension is imposed. | 02/04/2024 |
The securities of Jayex Technology Limited will be suspended from quotation immediately under Listing Rule 17.2, at the request of JTL, pending the release of its Annual Report for the year ended 31 December 2023. | 28/03/2024 |
The suspension of trading in the securities of Jayex Technology Limited will be lifted from the commencement of trading on Friday, 30 July 2021 following the release by JTL of an announcement regarding a strategic investment. | 30/07/2021 |
Jayex has signed a binding agreement for the investment of US$2 Million in cash into Brainworks' Foundry, Inc. Brainworks' AI technology platform is currently undergoing preliminary clinical trials and is designed to allow a patient's vital signs, incl. heart rate, respiratory rate, blood oxygenation to be measured simply by focusing a smart camera (phone, PC, TV) on the patient's face for 5-30 seconds. In addition, Brainworks has utilized existing technologies to develop a highly scalable polymerase chain reaction testing process, using next-generation gene sequencing and DNA barcoding that reduces cost and turnaround time. Post-COVID, Brainworks plans to diversify its platform to support additional viral and bacterial tests including influenza, Hepatitis, HIV, and other pathologies. | 30/07/2021 |
The securities of Jayex Technology Limited will be suspended from quotation immediately under Listing Rule 17.2, at the request of JTL, pending the release of an announcement regarding a strategic investment. | 28/07/2021 |
name changed from Jayex Healthcare Limited | 01/06/2021 |
Shareholders in this company should consider crystallising a capital loss in 2024/25 by selling their shares. This process is now much easier and quicker. It can be achieved online by entering transaction details here. While, this usually makes good economic sense we recommend you seek professional advice before buying or selling securities, your accountant is probably the best person. | 13/09/2024 |
delisted at entity's request under Listing Rule 17.11 | 06/08/2024 |
we understand the company delisted from ASX because of the lack of liquidity on ASX, difficulties associated with fundraising as a listed company, a disproportionate impact on share price of the small number of trades on ASX, costs of the listing and the fact the company's business is now entirely based in the UK | 06/08/2024 |
The company lodged its June 2024 Quarterly Activity Report and June 2024 Appendix 4C. | 05/08/2024 |
The securities of the Company will be suspended from quotation under Listing Rule 17.5 from the commencement of trading today, Thursday, 1 August 2024, for not lodging the relevant periodic report by the due date. If the report is lodged between the closure of the market announcements office on Wednesday, 31 July 2024, and the imposition of the suspension, the entity's securities will normally be reinstated to quotation on the next trading day after the suspension is imposed. | 01/08/2024 |
The suspension of trading in the securities of Jayex Technology Limited will be lifted from the commencement of trading on Monday, 6 May 2024 following lodgement of its Annual Report for the period ending 31 December 2023. | 03/05/2024 |
The company releases its Appendix 4G and Corporate Governance Statement. | 03/05/2024 |
The company releases its annual report. | 03/05/2024 |
The securities of the company will be suspended from quotation under Listing Rule 17.5 from the commencement of trading today, Tuesday, 2 April 2024, for not lodging the relevant periodic report by the due date. If the report is lodged between the closure of the market announcements office on Thursday, 28 March 2024, and the imposition of the suspension, the entity's securities will normally be reinstated to quotation on the next trading day after the suspension is imposed. | 02/04/2024 |
The securities of Jayex Technology Limited will be suspended from quotation immediately under Listing Rule 17.2, at the request of JTL, pending the release of its Annual Report for the year ended 31 December 2023. | 28/03/2024 |
The suspension of trading in the securities of Jayex Technology Limited will be lifted from the commencement of trading on Friday, 30 July 2021 following the release by JTL of an announcement regarding a strategic investment. | 30/07/2021 |
Jayex has signed a binding agreement for the investment of US$2 Million in cash into Brainworks' Foundry, Inc. Brainworks' AI technology platform is currently undergoing preliminary clinical trials and is designed to allow a patient's vital signs, incl. heart rate, respiratory rate, blood oxygenation to be measured simply by focusing a smart camera (phone, PC, TV) on the patient's face for 5-30 seconds. In addition, Brainworks has utilized existing technologies to develop a highly scalable polymerase chain reaction testing process, using next-generation gene sequencing and DNA barcoding that reduces cost and turnaround time. Post-COVID, Brainworks plans to diversify its platform to support additional viral and bacterial tests including influenza, Hepatitis, HIV, and other pathologies. | 30/07/2021 |
The securities of Jayex Technology Limited will be suspended from quotation immediately under Listing Rule 17.2, at the request of JTL, pending the release of an announcement regarding a strategic investment. | 28/07/2021 |
name changed from Jayex Healthcare Limited | 01/06/2021 |
Your browser may reflect a date of printing in American format.
Purchases Sales
| DATE | DIRECTOR | NATURE | NUMBER | PRICE | AMOUNT |
|---|---|---|---|---|---|
| 04/04/2023 | Michael Boyd | 3,000,000 | $0.010 | $31,267 | |
| 01/12/2022 | Michael Chan | 50,820 | $0.012 | $610 | |
| 30/06/2021 | Michael Chan | 20,000 | $0.027 | $540 | |
| 30/09/2020 | Michael Boyd | 1,500,000 | $0.035 | $52,500 | |
| 30/06/2020 | Michael Chan | 24,962 | $0.018 | $449 |
| NAME | TITLE | DATE OF APPT |
|---|---|---|
| Michael Boyd | Executive Chairman | 17/12/2015 |
| Robert Hadley | CEO, CFO | 03/10/2022 |
| Brian Renwick | Non Exec Director | 17/12/2015 |
| William Boyd | Non Exec Director | 04/06/2024 |
| Melanie Leydin | Company Secretary |
Date of first appointment, title may have changed.
| NAME | TITLE | DATE OF APPOINTMENT | DATE OF RESIGNATION |
|---|---|---|---|
| Michael Chan | Non Exec Director | 27/03/2017 | 04/06/2024 |
| Nick Harper | Non Exec Director | 02/09/2020 | 13/03/2024 |
| Nathan Woodard | CFO | 28/08/2018 | 31/01/2023 |
| Nick Fernando | Managing Director, CEO | 23/05/2017 | 25/07/2020 |
| Agam Jain | Non Exec Director | 14/01/2016 | 06/12/2019 |
| Cameron Knox | CFO | 15/01/2016 | 28/08/2018 |
| John Allinson | Non Exec Director | 17/12/2015 | 29/07/2016 |
| Shane Tanner | Non Exec Director | 17/12/2015 | 12/07/2016 |
Date of first appointment, title may have changed.
Contact Us | Financial Services Guide | Privacy Policy
This website is owned and operated by Investogain Pty Limited.
ABN 88 129 443 447 | AFSL 334036
Information provided is of a general nature and not for trading or advice.
Copyright © 2002-2024 Investogain Pty Limited. All rights reserved.
